{"id":250923,"date":"2022-05-20T00:00:00","date_gmt":"2022-05-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidmd0082-biopharma-metachromatic-leukodystrophy-epidemiology\/"},"modified":"2026-03-31T10:39:28","modified_gmt":"2026-03-31T10:39:28","slug":"epidmd0082-biopharma-metachromatic-leukodystrophy-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0082-biopharma-metachromatic-leukodystrophy-epidemiology-mature-markets\/","title":{"rendered":"Metachromatic Leukodystrophy &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of metachromatic leukodystrophy (<abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr> forecast will answer the following question:<\/p>\n<ul>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate\u00a0Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr> patient populations:<\/p>\n<ul>\n<li>Diagnosed prevalence of <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr>.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr> (late infantile).<\/li>\n<li>Diagnosed prevalence of <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr> (juvenile).<\/li>\n<li>Diagnosed prevalence of <abbr title=\"metachromatic leukodystrophy\">MLD<\/abbr> (adult).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250923","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250923\/revisions"}],"predecessor-version":[{"id":283302,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250923\/revisions\/283302"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}